542 related articles for article (PubMed ID: 29376557)
1. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
3. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
[TBL] [Abstract][Full Text] [Related]
4. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
[TBL] [Abstract][Full Text] [Related]
5. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.
Kattakuzhy S; Wilson E; Sidharthan S; Sims Z; McLaughlin M; Price A; Silk R; Gross C; Akoth E; McManus M; Emmanuel B; Shrivastava S; Tang L; Nelson A; Teferi G; Chavez J; Lam B; Mo H; Osinusi A; Polis MA; Masur H; Kohli A; Kottilil S
Clin Infect Dis; 2016 Feb; 62(4):440-447. PubMed ID: 26503379
[TBL] [Abstract][Full Text] [Related]
6. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
7. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
8. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment.
Daniel KE; Saeian K; Rizvi S
J Viral Hepat; 2020 Feb; 27(2):195-204. PubMed ID: 31602715
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.
Scherz N; Bruggmann P; Brunner N
Int J Drug Policy; 2018 Dec; 62():74-77. PubMed ID: 30368101
[TBL] [Abstract][Full Text] [Related]
11. Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.
Elhence A; Singh A; Anand A; Kumar R; Ashraf A; Kumar S; Pradhan D; Pathak P; Vaishnav M; Rajput MS; Banyal V; Nayak B; Shalimar
J Med Virol; 2021 Aug; 93(8):4982-4991. PubMed ID: 33783006
[TBL] [Abstract][Full Text] [Related]
12. Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients.
Carrasco I; Arias A; Benítez-Gutiérrez L; Lledó G; Requena S; Cuesta M; Cuervas-Mons V; de Mendoza C
J Med Virol; 2018 Mar; 90(3):532-536. PubMed ID: 28990680
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
[TBL] [Abstract][Full Text] [Related]
14. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V
J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
16. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
17. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R).
Schmitt A; Günther R; Mauss S; Boeker KHW; Buggisch P; Hillenbrand H; John C; Klinker H; Pathil A; Simon KG; Serfert Y; Niederau C; Vermehren J; Wedemeyer H; Sarrazin C
Z Gastroenterol; 2020 Apr; 58(4):341-351. PubMed ID: 32040979
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.
Dammermann W; Polywka S; Dettmann I; Mindorf S; Komorowski L; Wehmeyer M; Schulze Zur Wiesch J; Stöcker W; Lüth S
Med Microbiol Immunol; 2017 Oct; 206(5):379-382. PubMed ID: 28815296
[TBL] [Abstract][Full Text] [Related]
19. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?
Beinhardt S; Staettermayer AF; Rutter K; Maresch J; Scherzer TM; Steindl-Munda P; Hofer H; Ferenci P
Hepatology; 2012 Jan; 55(1):30-8. PubMed ID: 21932410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
